UPDATED RECOMMENDATIONS ON
TREATMENT OF ADOLESCENTS AND
CHILDREN WITH CHRONIC HCV INFECTION,
AND HCV SIMPLIFIED SERVICE DELIVERY
AND DIAGNOSTICS

WEB ANNEX A: SUMMARY OF DECLARATIONS
OF CONFLICTS OF INTEREST
UPDATED RECOMMENDATIONS ON
TREATMENT OF ADOLESCENTS AND
CHILDREN WITH CHRONIC HCV INFECTION,
AND HCV SIMPLIFIED SERVICE DELIVERY
AND DIAGNOSTICS

WEB ANNEX A: SUMMARY OF DECLARATIONS
OF CONFLICTS OF INTEREST
Web Annex A. Summary of declarations of conflicts of interest

Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and HCV diagnostics. Web Annex A. Summary of declarations of conflicts of interest


© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).


Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication forms part of the WHO guideline entitled Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and HCV diagnostics. It is being made publicly available for transparency purposes and information, in accordance with the WHO handbook for guideline development, 2nd edition (2014).
### Summary of declarations of significant conflicts of interest:

**Guideline Development Group**

<table>
<thead>
<tr>
<th>Name</th>
<th>Conflict of interest declared</th>
<th>Action taken</th>
</tr>
</thead>
</table>
| **Jason Grebely** | **2a: Research support, including grants, collaborations, sponsorships and other funding**  
Cepheid: US$ 3 000 000 (current); Gilead Sciences: US$ 1 500 000 (current); Hologic: US$ 250 000 (current)  
As part of National Health and Medical Research Council Partnership project grants on which I am the chief investigator. These are grants from the Australia federal government, with partner contributions to the grants (called NHMRC Partnership Project Grants).  
- A national programme to scale up point-of-care hepatitis C testing and treatment (Australian Department of Health: US$ 6.5 million; Gilead Sciences: US$ 720 000; Cepheid: US$ 1.9 million in-kind, cartridges and platforms)  
- Enhancing hepatitis C testing and treatment among people who inject drugs attending needle and syringe programmes: the TEMPO Study (National Health and Medical Research Council: US$ 1 396 395; Gilead Sciences: US$ 668 353; Cepheid: US$ 1.5 million in-kind, cartridges and platforms; Hologic: US$ 150 000 in-kind, HCV RNA tests)  
 **2b: Non-monetary support valued at more than US$ 1000 overall:**  
AbbVie: US$ 5000 (2020); Cepheid: US$ 3000 (2020); Gilead Sciences: US$ 3000 (2021) | Partial exclusion - Non-voting for the HCV point-of-care viral load topic. Contribute as expert or presenter to this session.                                                                                                                                                                      |
| **Christian B. Ramers** | **1b: Consulting:** Targeted HCV Elimination Steering Committee AbbVie self US$ 1500 current  
**2a: Research support**  
Pragmatic clinical trial – mobile HCV treatment of people who inject drugs at syringe exchange site – STAT programme, Gilead Sciences research unit, US$ 637 500 current [Investigator-led study undertaken by colleague Sarah Rojas entitled “Does a simplified algorithm and integrated HCV care improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial”. Four-year study embedded in our syringe-exchange services in which we are assigning HCV patients to either be evaluated and treated in a mobile van with mobile FibroScan® and phlebotomy services or traditional in-clinic evaluation and treatment. Grant received by institution but not involved in this project; not in receipt of funds.  
**2b: HCV speakers bureau** (therapeutics), Gilead Sciences, self, US$ 2000, current  
**2b: HCV speakers bureau** (therapeutics), AbbVie, self, US$ 2000, current | Investigator-driven projects, not principal investigator. Declared interests perceived not in conflict with Guideline Development Group topics |

---

**Notes:**
- All values are in US dollars.
- Dates are as of the time of declaration.
- **a:** Research support
- **b:** Non-monetary support valued at more than US$ 1000 overall.
### Lai Wei

**1b: Consulting**
- Gilead: US$ 1000 (2020); Huahui: US$ 2000 (2021); MSD: US$ 500 (2019); Pfizer: US$ 1,000 (2021)

**1b: Speaker**

**2a: Research grants**
- BMS: US$ 100 000 (2015–2018) – Support for HCV genotyping in China
- **Gilead: US$ 200 000 (2021) (institution)** – development of algorithm to support linkage to care following testing in 50 hospitals

---

Only one project active – linkage to care project not linked to one company’s drugs. Declared interests perceived not in conflict with Guideline Development Group topics.